Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

肿瘤的研究一直是生命科学和基础医学领域中的热门话题，随着分子生物学和肿瘤生物学等学科的发展，人们逐渐明确了一系列与肿瘤发生和转移等密切关系的基因、蛋白，包括多种受体酪氨酸激酶（RTKs，如EGFR、ALK、c-Met、TRK、BCR-ABL等）和非R ...

Objective Autophagy participates in the progression of hepatocellular carcinoma (HCC) and the resistance of HCC cells to sorafenib. We investigated the feasibility of sensitising HCC cells to ...

Background: Hepatic arterial infusion (HAI) of oxaliplatin, leucovorin, and fluorouracil (FOLFOX) plus sorafenib has a more desirable effect versus sorafenib for hepatocellular carcinoma (HCC) ...

More importantly, the AGI could accurately predict tumor sensitivity to Sorafenib therapy. Therefore, the AGI may be a promising biomarker that can accurately stratify patients and improve their ...

经过DataTwin图像查重流程，发现李春晓、江萍、王俊杰团队等人近期在某权威期刊上发表的"Sorafenib enhanced the function of myeloid-derived suppressor cells in ...

Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

编者按：在近期召开的巴黎2025 EASL肝癌峰会上，由全球肝癌领域权威专家、美国纪念斯隆-凯特琳癌症中心Ghassan ...

The panelist discusses first-line options including atezolizumab plus bevacizumab, lenvatinib, and sorafenib. Second-line treatments include regorafenib, cabozantinib, and ramucirumab. Clinical trials ...

值得关注的是，在近日召开的美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）上，CheckMate 9DW 研究进一步公布其扩展分析结果，再次证实了 O+Y 双免治疗的长生存获益，为其作为晚期 HCC 的一线治疗方案提供了坚实的循证医学支持 ...